See more : Medistim ASA (0OCD.L) Income Statement Analysis – Financial Results
Complete financial analysis of bioAffinity Technologies, Inc. (BIAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of bioAffinity Technologies, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Jinlong Machinery & Electronic Co.,Ltd (300032.SZ) Income Statement Analysis – Financial Results
- HEPHAIST Co., Ltd. (6433.T) Income Statement Analysis – Financial Results
- Shenzhen Original Advanced Compounds Co., Ltd. (603991.SS) Income Statement Analysis – Financial Results
- G.P. Global Power Ltd (GPGB-M.TA) Income Statement Analysis – Financial Results
- AGCO Corporation (AGCO) Income Statement Analysis – Financial Results
bioAffinity Technologies, Inc. (BIAF)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.bioaffinitytech.com
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.53M | 4.80K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 467.00 | 4.82K | 22.24K | 40.28K |
| Gross Profit | 791.62K | 4.34K | -4.82K | -22.24K | -40.28K |
| Gross Profit Ratio | 31.26% | 90.28% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.72M | 1.29M | 1.33M | 1.61M | 1.85M |
| General & Administrative | 0.00 | 2.73M | 880.77K | 994.34K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.79M | 2.73M | 880.77K | 994.34K | 1.20M |
| Other Expenses | 249.59K | -1.87M | 724.93K | -4.28M | 0.00 |
| Operating Expenses | 8.76M | 4.02M | 2.21M | 2.60M | 3.05M |
| Cost & Expenses | 10.51M | 4.02M | 2.21M | 2.60M | 3.09M |
| Interest Income | 122.13K | 46.71K | 424.00 | 1.07K | 2.78K |
| Interest Expense | 37.13K | 2.53M | 1.00M | 382.17K | 214.83K |
| Depreciation & Amortization | 249.59K | 10.18K | 4.82K | 22.24K | 40.28K |
| EBITDA | -7.63M | -5.61M | -2.20M | -6.86M | -3.05M |
| EBITDA Ratio | -301.26% | -121,196.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.97M | -4.01M | -2.21M | -2.60M | -3.09M |
| Operating Income Ratio | -314.84% | -83,511.51% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 57.21K | -4.14M | -4.12M | -4.66M | -212.06K |
| Income Before Tax | -7.92M | -8.15M | -6.32M | -7.27M | -3.30M |
| Income Before Tax Ratio | -312.58% | -169,720.05% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 20.99K | 2.46K | 1.95K | 2.75K | 3.20K |
| Net Income | -7.94M | -8.15M | -6.33M | -7.27M | -3.31M |
| Net Income Ratio | -313.41% | -169,771.25% | 0.00% | 0.00% | 0.00% |
| EPS | -0.91 | -1.81 | -0.86 | -0.99 | -0.45 |
| EPS Diluted | -0.91 | -1.81 | -0.86 | -0.99 | -0.45 |
| Weighted Avg Shares Out | 8.75M | 4.50M | 7.38M | 7.38M | 7.38M |
| Weighted Avg Shares Out (Dil) | 8.75M | 4.50M | 7.38M | 7.38M | 7.38M |
bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports 375% growth in sales of CyPath Lung tests in recent months.
bioAffinity Technologies In The News
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Summary of the latest news about bioAffinity Technologies.
bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Indian Patent Office issues patent to bioAffinity Technologies for porphyrin compounds related to targeted cancer treatment.
bioAffinity Technologies In the News
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--A summary of latest news about bioAffinity Technologies and CyPath® Lung, its noninvasive test for the detection of early-stage lung cancer.
bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January...
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Jamie Platt, Ph.D., joins the bioAffinity Technologies Board of Directors.
CMS Posts Final Payment Determination for bioAffinity Technologies' CyPath® Lung Effective January 2024
SAN ANTONIO,--(BUSINESS WIRE)-- #BIAF--CMS has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.
bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
SAN ANTONIO--(BUSINESS WIRE)-- #ASCB--bioAffinity Technologies VP of Research David Elzi, Ph.D., named to post with the American Society for Cell Biology.
bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today launched a campaign in partnership with the ACS to increase lung cancer screening in Texas.
bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports third quarter 2023 financial results and provides business update.
Source: https://incomestatements.info
Category: Stock Reports